Pay in 4 interest-free payments of $6.38 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
(Nasdaq: GUTS) (the Company or Fractyl), a clinical-stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today announced positive one-year results from its open-label REVEAL-1 Cohort
The calibration and validation results show that both in the control and the rd1 case, the model produces output for [GSH] and [GSSG] approximating trends in the experimental data, and there is notable uncertainty in the estimated parameters
Neuropathology Exp
Selecting among alternatives requires clinical evaluation by a qualified provider
US$ 28.83
US$ 28.89
US$ 26.18
US$ 22.50
US$ 24.37
US$ 28.01
